Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 1, 2013, Pages 469-470

  Rauck, Britta M ^a,b   Friberg, Thomas R ^a,c   Medina Mendez, Carlos A ^c   Park, Daewon ^a,f   Shah, Veeral ^c   Bilonick, Richard A ^b,c,d   Wang, Yadong ^a,b,e  

^a University of Pittsburgh   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f The University of Colorado Denver   (United States)

Author keywords

Biocompatibility; Injectable gel; Ocular drug delivery; Sustained release; Thermally responsive hydrogel

Indexed keywords

BEVACIZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; HYDROGEL; INTRAOCULAR PRESSURE; MALE; NONHUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; RABBIT;

EID: 84893141968     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13120     Document Type: Article

References (31)

1. Kinnunen K, Yla-Herttuala S. Vascular endothelial growth factors in retinal and choroidal neovascular diseases. Ann Med. 2012;44:1-17.
2. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929-1934.
3. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, deJong P. Increased expression of angiogenic growth factors in agerelated maculopathy. Br J Ophthalmol. 1997;81:154-162.
4. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:3158-3164.
5. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695. e1-1695. e15.
6. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother. 2007;41:614-625.
7. Kleinman ME, Ambati J. Pathophysiology of retinal neovascularization. In: Pine JW, ed. Therapy for Ocular Angiogenesis: Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.
8. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508-512.
9. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-2182.
10. D'Amico DJ. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006;113:992-1001.
11. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008;28:1395-1399.
12. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663-671.
13. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239-248.
14. Li F, Hurley B, Liu Y, Leonard B, Griffith M. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol J. 2012;6:54-58.
15. Pan CK, Durairaj C, Kompella UB, et al. Comparison of longacting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther. 2011;27:219-224.
16. Kang Derwent JJ, Mieler WF. Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. Trans Am Ophthalmol Soc. 2008;106:206-213, discussion 213-204.
17. Turturro SB, Guthrie MJ, Appel AA, et al. The effects of cross-linked thermo-responsive PNIPAAm-based hydrogel injection on retinal function. Biomaterials. 2011;32:3620-3626.
18. Park D, Wu W, Wang Y. A functionalizable reverse thermal gel based on a polyurethane/PEG block copolymer. Biomaterials. 2011;32:777-786.
19. Park D, Shah V, Rauck BM, Friberg TR, Wang Y. An antiangiogenic reverse thermal gel as a drug-delivery system for age-related wet macular degeneration. Macromol Biosci. 2013;13:464-469.
20. The R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2012.
21. Pinheiro J, Bates D, Debroy S, Sarkar D, and the R Development Core Team. nlme: Linear and Nonlinear Mixed Effects Models. R Package version 3.1-108, 2013.
22. Friberg TR, Siska PE, Somayajula K, Williams J, Eller AW. Interactions of perfluorocarbon liquids and silicone oil as characterized by mass spectrometry. Graefe's Arch Clin Exp Ophthalmol. 2003;241:809-815.
23. Friberg TR, Verstraeten TC, Wilcox DK. Effects of emulsification, purity, and fluorination of silicone oil on human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1991;32: 2030-2034.
24. Pruett RC, Schepens CL, Swann DA. Hyaluronic acid vitreous substitute. A six-year clinical evaluation. Arch Ophthalmol. 1979;97:2325-2330.
25. Schramm C, Spitzer MS, Henke-Fahle S, et al. The cross-linked biopolymer hyaluronic acid as an artificial vitreous substitute. Invest Ophthalmol Vis Sci. 2012;53:613-621.
26. Sniegowski M, Mandava N, Kahook MY. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J. 2010;4:28-29.
27. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21:178-183.
28. Wang CH, Hwang YS, Chiang PR, Shen CR, Hong WH, Hsiue GH. Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel. Biomacromolecules. 2011;13:40-48.
29. Hwang YS, Chiang PR, Hong WH, et al. Study in vivo intraocular biocompatibility of in situ gelation hydrogels: poly(2-ethyl oxazoline)-block-poly(epsilon-caprolactone)-block-poly(2-ethyl oxazoline) copolymer, matrigel and pluronic F127. PLoS One. 2013;8:e67495.
30. Streilein JW, Takeuchi M, Taylor AW. Immune privilege, T-cell tolerance, and tissue-restricted autoimmunity. Hum Immunol. 1997;52:138-143.
31. Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefe's Arch Clin Exp Ophthalmol. 2009;247:171-177.